معرفی
Carolyn Lam is affiliated with the Faculty of Medical Sciences at the University of Groningen, specifically within the Cardiovascular Centre (CVC) at the UMCG. Her primary research focuses on heart failure, particularly exploring mechanisms and treatments in heart failure with preserved and reduced ejection fractions (HFpEF/HFrEF). She collaborates internationally on trials such as VICTOR and STRONG-HF, investigating clinical outcomes and biomarkers.
Her research interests include the pathophysiology of heart failure, the role of liver function tests in acute heart failure prognosis, and gender differences in new-onset heart failure. She also examines the efficacy of drugs like finerenone in managing heart failure and chronic kidney disease in patients with type 2 diabetes.
Recent work highlights analyses of baseline characteristics in HF patients (VICTOR trial), liver function changes post-acute HF (STRONG-HF trial), and finerenone’s impact on quality of life metrics in HFpEF patients. These studies emphasize translational research linking clinical trials to patient outcomes.
Supervised Work (3) indicates her mentorship roles, though specific advisees aren’t listed here. Her affiliation with the Cardiovascular Centre (CVC) suggests involvement in collaborative teams focused on cardiovascular medicine and heart failure management.
